Compare XXII & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | POAI |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.5M |
| IPO Year | N/A | N/A |
| Metric | XXII | POAI |
|---|---|---|
| Price | $0.97 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 191.6K | 42.7K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,346,000.00 | $1,664,407.00 |
| Revenue This Year | N/A | $486.27 |
| Revenue Next Year | $136.46 | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 16.98 | ★ 320.71 |
| 52 Week Low | $0.78 | $3.88 |
| 52 Week High | $287.27 | $45.90 |
| Indicator | XXII | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 47.30 |
| Support Level | $1.06 | $3.88 |
| Resistance Level | $1.17 | $6.25 |
| Average True Range (ATR) | 0.09 | 0.76 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 39.94 | 79.01 |
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.